Document is current
Any future updates will be listed below
-
Authors
Uppugunduri, C. R. S. http://orcid.org/0000-0002-8928-7049
Huezo-Diaz Curtis, P. http://orcid.org/0000-0001-6949-5185
Nava, T.
Rezgui, M. A.
Mlakar, V. http://orcid.org/0000-0003-4968-5592
Mlakar, S. Jurkovic http://orcid.org/0000-0002-2552-456X
Waespe, N. http://orcid.org/0000-0002-2271-8959
Théoret, Y.
Gumy-Pause, F.
Bernard, F.
Chalandon, Y. http://orcid.org/0000-0001-9341-8104
Boelens, J. J.
Bredius, R. G. M.
Dalle, J. H.
Nath, C. http://orcid.org/0000-0002-1013-3646
Corbacioglu, S.
Peters, C. http://orcid.org/0000-0003-0369-8515
Bader, P.
Shaw, P.
Bittencourt, H. http://orcid.org/0000-0002-5507-8310
Krajinovic, M. http://orcid.org/0000-0003-4772-7031
Ansari, M. http://orcid.org/0000-0002-9649-6498
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030-153389)
Oak Foundation
CANSESARCH Foundation, Oak Foundation
CANSEARCH Foundation
CANSEARCH Foundation, Oak Foundation
CANSEARCH FOUNDATION
The Leukaemia Research and Support Fund
- License Information
-
More Information
Article History
Received: 11 November 2020
Revised: 26 February 2021
Accepted: 6 April 2021
First Online: 28 October 2021
Competing interests
: None to declare related to the submitted work. Outside the submitted work, BH has received honoraria from Jazz Pharmacueticals and Novartis. JJB has received honoraria from Avrobio, Advanced Clinical, BlueRock, Omeros, Race oncology, and Takeda Pharmaceuticals. CY has received honoraria from INCYTE, ABBVIE, GILEAD, ROCHE, Astra-Zeneca, Jazz Pharmaceuticals, and MSD.
